EN PL

News

GMP: Risk Assessment for ascertaining GMP for Excipients

05.12.2013
The EU has published the comments received from the industry regarding the publication of the draft guidelines on the formalised risk assessment for ascertaining the appropriate good manufacturing ...

EC: Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use

28.11.2013
The Commission has published EU Guidelines on Good Distribution Practice (GDP) in 1994. Revised guidelines were published in March 2013 in order to take into account recent advances in practices ...

EMA: Draft guideline on the adventitious agent safety of urine-derived medicinal products

28.11.2013
Human urine is used to prepare several products indicated in the field of endocrinology, such as human chorionic gonadotropin (hCG), human menopausal gonadotropin or menotropin (HMG) and ...

URPL: Announcement of President of The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products concerning conveying applications regarding serious adverse reaction of medicinal products from Office for Registration to MAH.

28.11.2013
This document is an announcement of President of The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products concerning conveying applications regarding serious ...

GMP: Guidelines on GDP revised

28.11.2013
Only eight months after their publication, the Guidelines from 7 March 2013 on Good Distribution Practice of Medicinal Products for Human Use have been revised. ...

EMA: EMA promotes consistent development of bioequivalence studies through product-specific guidance

21.11.2013
The European Medicines Agency has released its first product-specific guidance on the demonstration of bioequivalence for 16 active substances. ...

EMA: Second draft public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs)

21.11.2013
It became apparent during assessment of Symphytum officinale (monograph EMEA/HMPC/572844/2009) that the risk assessment of pyrrolizidine alkaloids (PAs) poses considerable difficulties, with ...

Polish Ministry of Health: Project of regulation of Minister of Health concerning a way and mode of pharmacovigilance of veterinary medicinal products.

21.11.2013
This document is a project of regulation of Minister of Health concerning a way and mode of pharmacovigilance of veterinary medicinal products. ...

EMA: Second draft guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation

21.11.2013
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. AF confers a 5-fold risk of stroke, and one in five of all strokes is ...

EMA: New EMA guidance on development of antibacterials to help in the fight against multidrug-resistant pathogens

14.11.2013
The European Medicines Agency (EMA) released an Addendum to the guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections. One of the most important ...